Main Library
Here’s how finance leaders can evaluate AI investments in revenue cycle management before committing budget, and the risk exposure most vendor pitches leave out.
Every healthcare CFO’s inbox now has an AI-in-RCM pitch in it. The promises are consistent: lower denial rates, faster collections, leaner overhead. What’s inconsistent is the due diligence behind the decision to buy.
Most of these deals are still evaluated like traditional software purchases: features, price, timeline. That framework misses what actually determines whether an AI investment pays off or becomes a costly write-off eighteen months later: data readiness, workforce redesign, and governance exposure that never show up on a vendor’s feature sheet.
Before approving a budget for AI in revenue cycle management, CFOs should be asking seven specific questions, and most vendors are hoping they won’t.